Deep learning models predict regulatory variants in pancreatic islets and refine type 2 diabetes association signals

Abstract

Genome-wide association analyses have uncovered multiple genomic regions associated with T2D, but identification of the causal variants at these remains a challenge. There is growing interest in the potential of deep learning models - which predict epigenome features from DNA sequence - to support inference concerning the regulatory effects of disease-associated variants. Here, we evaluate the advantages of training convolutional neural network (CNN) models on a broad set of epigenomic features collected in a single disease-relevant tissue – pancreatic islets in the case of type 2 diabetes (T2D) - as opposed to models trained on multiple human tissues. We report convergence of CNN-based metrics of regulatory function with conventional approaches to variant prioritization – genetic fine-mapping and regulatory annotation enrichment. We demonstrate that CNN-based analyses can refine association signals at T2D-associated loci and provide experimental validation for one such signal. We anticipate that these approaches will become routine in downstream analyses of GWAS.

Data availability

The datasets analysed during the current study are available in the public repositories under accessions listed in STable 1.

The following previously published data sets were used

Article and author information

Author details

  1. Agata Wesolowska-Andersen

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8688-2814
  2. Grace Zhuo Yu

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  3. Vibe Nylander

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  4. Fernando Abaitua

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  5. Matthias Thurner

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7329-9769
  6. Jason M Torres

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7537-7035
  7. Anubha Mahajan

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  8. Anna L Gloyn

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1205-1844
  9. Mark I McCarthy

    Department of Human Genetics, Genentech, South San Francisco, United States
    For correspondence
    mark.mccarthy@drl.ox.ac.uk
    Competing interests
    Mark I McCarthy, Senior editor, eLife; has served on advisory panels for Pfizer, NovoNordisk, Zoe Global; has received honoraria from Merck, Pfizer, NovoNordisk and Eli Lilly; has stock options in Zoe Global and has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier & Takeda. As of June 2019, is an employee of Genentech, and holds stock in Roche.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4393-0510

Funding

Wellcome (099673/Z/12/Z)

  • Matthias Thurner

Horizon 2020 Framework Programme (T2D Systems)

  • Anna L Gloyn

NIH Clinical Center (U01-DK105535)

  • Anna L Gloyn
  • Mark I McCarthy

NIH Clinical Center (U01-DK085545)

  • Anna L Gloyn

National Institute for Health Research (NF-SI-0617-10090)

  • Anna L Gloyn

Wellcome (090532)

  • Mark I McCarthy

Wellcome (106130)

  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (098381)

  • Mark I McCarthy

Wellcome (203141)

  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (212259)

  • Mark I McCarthy

Wellcome (095101)

  • Anna L Gloyn

Wellcome (200837)

  • Anna L Gloyn

Medical Research Council (MR/L020149/1)

  • Anna L Gloyn

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Wesolowska-Andersen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,137
    views
  • 628
    downloads
  • 27
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Agata Wesolowska-Andersen
  2. Grace Zhuo Yu
  3. Vibe Nylander
  4. Fernando Abaitua
  5. Matthias Thurner
  6. Jason M Torres
  7. Anubha Mahajan
  8. Anna L Gloyn
  9. Mark I McCarthy
(2020)
Deep learning models predict regulatory variants in pancreatic islets and refine type 2 diabetes association signals
eLife 9:e51503.
https://doi.org/10.7554/eLife.51503

Share this article

https://doi.org/10.7554/eLife.51503

Further reading

    1. Computational and Systems Biology
    2. Microbiology and Infectious Disease
    Gaetan De Waele, Gerben Menschaert, Willem Waegeman
    Research Article

    Timely and effective use of antimicrobial drugs can improve patient outcomes, as well as help safeguard against resistance development. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is currently routinely used in clinical diagnostics for rapid species identification. Mining additional data from said spectra in the form of antimicrobial resistance (AMR) profiles is, therefore, highly promising. Such AMR profiles could serve as a drop-in solution for drastically improving treatment efficiency, effectiveness, and costs. This study endeavors to develop the first machine learning models capable of predicting AMR profiles for the whole repertoire of species and drugs encountered in clinical microbiology. The resulting models can be interpreted as drug recommender systems for infectious diseases. We find that our dual-branch method delivers considerably higher performance compared to previous approaches. In addition, experiments show that the models can be efficiently fine-tuned to data from other clinical laboratories. MALDI-TOF-based AMR recommender systems can, hence, greatly extend the value of MALDI-TOF MS for clinical diagnostics. All code supporting this study is distributed on PyPI and is packaged at https://github.com/gdewael/maldi-nn.

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Sanjarbek Hudaiberdiev, Ivan Ovcharenko
    Research Article

    Enhancers and promoters are classically considered to be bound by a small set of transcription factors (TFs) in a sequence-specific manner. This assumption has come under increasing skepticism as the datasets of ChIP-seq assays of TFs have expanded. In particular, high-occupancy target (HOT) loci attract hundreds of TFs with often no detectable correlation between ChIP-seq peaks and DNA-binding motif presence. Here, we used a set of 1003 TF ChIP-seq datasets (HepG2, K562, H1) to analyze the patterns of ChIP-seq peak co-occurrence in combination with functional genomics datasets. We identified 43,891 HOT loci forming at the promoter (53%) and enhancer (47%) regions. HOT promoters regulate housekeeping genes, whereas HOT enhancers are involved in tissue-specific process regulation. HOT loci form the foundation of human super-enhancers and evolve under strong negative selection, with some of these loci being located in ultraconserved regions. Sequence-based classification analysis of HOT loci suggested that their formation is driven by the sequence features, and the density of mapped ChIP-seq peaks across TF-bound loci correlates with sequence features and the expression level of flanking genes. Based on the affinities to bind to promoters and enhancers we detected five distinct clusters of TFs that form the core of the HOT loci. We report an abundance of HOT loci in the human genome and a commitment of 51% of all TF ChIP-seq binding events to HOT locus formation thus challenging the classical model of enhancer activity and propose a model of HOT locus formation based on the existence of large transcriptional condensates.